Login
Vericel NASDAQ: VCEL
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
| Name | Vericel |
| Ticker | VCEL |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
|
Price
52W Low/High |
53.10
13.03 / 64.05 |
| Momentum | Neutral |
| Market cap | 2.4 B |
| 1Y Total Return |
255.90%
Strong |
| 1Y Volatility |
54.52%
More Risk |
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
Details
| Ticker | VCEL |
| Name | Vericel |
| ISIN | US92346J1088 |
| CUSIP | 92346J108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 5/6/21
| Close Price | 53.10 |
| 52W Low/High | 13.03 / 64.05 |
| Market cap | 2.4 B |
| 1Y Total Return |
255.90%
Strong |
| 1Y Volatility |
54.52%
More Risk |
| Beta | -0.30 |
| PE (trailing) |
531.00
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 3.2% |
| Cash from Op. / Cur. Liabilities | 0.99 |
| Diluted Earnings / Share | 0.10 |
| ROE | 3.4% |
| ROIC | 4.4% |
| Price / Revenue | 18.5 |
| Price / Book | 17.4 |
| Price / CF | 106.3 |
| Current Ratio | 5.5 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.37 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
132
|
123
|
95
|
73
|
50
|
54
|
|
| Gross Profit |
90
|
84
|
62
|
42
|
21
|
27
|
|
| R&D |
13
|
31
|
13
|
13
|
15
|
18
|
|
| EBITDA |
6
|
-10
|
0
|
-12
|
-23
|
-13
|
|
| Operating Income |
4
|
-13
|
-3
|
-10
|
-27
|
-14
|
|
| Net Income exc. Extra |
4
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
46
|
45
|
44
|
36
|
32
|
23
|
|
| EPS exc. Extra |
0.10
|
-0.26
|
-0.07
|
-0.42
|
-1.25
|
-0.94
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
211
|
150
|
141
|
52
|
41
|
33
|
|
| Cash, Eq & Invt ShortTerm |
84
|
82
|
84
|
30
|
20
|
14
|
|
| Total Current Assets |
127
|
117
|
110
|
48
|
37
|
26
|
|
| Total Non-Current Assets |
84
|
34
|
32
|
4
|
4
|
7
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
3
|
|
| Total Liabilities |
71
|
40
|
38
|
31
|
25
|
14
|
|
| Total Current Liabilities |
23
|
18
|
13
|
14
|
15
|
14
|
|
| Long Term Debt |
48
|
22
|
25
|
18
|
10
|
0
|
|
| Shareholder equity |
140
|
110
|
103
|
21
|
16
|
19
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
23
|
-3
|
-1
|
-10
|
-22
|
-11
|
|
| Depreciation |
2
|
2
|
2
|
2
|
2
|
2
|
|
| Cash from Investing |
-19
|
9
|
-51
|
-2
|
-2
|
-2
|
|
| Capex |
4
|
3
|
3
|
2
|
1
|
2
|
|
| Cash from Financing |
8
|
5
|
57
|
21
|
30
|
0
|
|
| Stock Issued |
10
|
5
|
75
|
15
|
19
|
0
|
|
| Debt (LT) Issued |
0
|
0
|
-18
|
7
|
10
|
0
|
|
| Free Cash Flow |
-2
|
-22
|
-14
|
-20
|
-27
|
-18
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
3.2%
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
554.5%
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.5
|
6.4
|
8.5
|
3.5
|
2.5
|
1.9
|
|
| Financial Leverage D/E |
0.37
|
0.25
|
0.27
|
0.82
|
0.65
|
0.00
|
|
| Return on Capital Avg |
4.4%
|
-12.8%
|
-4.0%
|
-188.4%
|
-428.2%
|
-258.2%
|
|
| Return on Shareholder Equity |
3.4%
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available